A widely used supplement for joint pain may accelerate the progression of osteoarthritis in some patients, according to new research published in a leading rheumatology journal. The findings challenge long-held assumptions about the safety of glucosamine and chondroitin, ingredients found in millions of over-the-counter products taken daily by people managing arthritis symptoms.
Key Findings
- A six-year study of 600 patients with early-stage osteoarthritis found those taking glucosamine-chondroitin supplements experienced a 23% faster decline in joint space width—a key marker of cartilage loss—compared to those on placebo.
- The effect was most pronounced in patients with knee osteoarthritis, where progression was 30% faster in the supplement group.
- Researchers emphasized the results apply only to supplements, not prescription medications for osteoarthritis.
Why the Study Raises Concerns
For decades, glucosamine and chondroitin have been marketed as natural alternatives to pain relievers for osteoarthritis, a degenerative joint disease affecting over 32 million Americans. The new research, conducted by the Arthritis Research Center at Boston University, contradicts earlier smaller studies that suggested the supplements might slow cartilage breakdown.
Dr. Elena Vasquez, lead author of the study, said the findings were unexpected but clear: “We saw a consistent pattern across multiple measures of joint health. This isn’t just a statistical blip—it’s a real signal that warrants attention.” The study followed patients for six years, tracking joint space width via X-rays and pain levels through standardized questionnaires.
How the Results Compare to Past Research
The Boston University study stands in sharp contrast to a 2006 meta-analysis published in The New England Journal of Medicine, which found glucosamine-chondroitin provided modest pain relief but no clear benefit for joint structure. That analysis had been cited by health agencies, including the FDA, in guidance on arthritis supplements. The new data suggests those earlier conclusions may have been incomplete.
Dr. Michael Chen, a rheumatologist at the Cleveland Clinic who was not involved in the study, noted the discrepancy: “The 2006 findings were based on shorter trials—most under two years. Osteoarthritis is a slow, progressive disease. You can’t detect structural changes in six months that might show up after six years.”
What Experts Recommend—And What Patients Should Do
Health authorities have not yet updated their guidance, but several experts urged caution. The Arthritis Foundation, which previously supported glucosamine-chondroitin use, issued a statement advising patients to consult their doctors before continuing supplements. “This study doesn’t mean these products are dangerous for everyone,” said Dr. Vasquez. “But for people with early osteoarthritis, the risk of accelerating joint damage may outweigh any potential benefits.”
Dr. Chen added that the findings do not apply to prescription medications like hyaluronic acid injections, which work differently. “This is specifically about oral supplements. Patients on NSAIDs or other treatments should discuss alternatives with their providers.”
Limitations and Unanswered Questions
The study has several key limitations that researchers and clinicians emphasize. First, it was observational and did not prove causation—only an association between supplement use and faster joint deterioration. Second, the participants were predominantly white and middle-aged, which may limit how widely the results apply. Finally, the study did not track long-term effects beyond six years.
Dr. Vasquez acknowledged these gaps: “We need larger, randomized trials to confirm whether this is a real risk. But given how widely these supplements are used, even a modest acceleration of osteoarthritis could have significant public health implications.”
What Happens Next?
The FDA has not yet reviewed the study, but the Arthritis Research Center plans to present the findings at the American College of Rheumatology’s annual meeting in November. Researchers are also calling for a large-scale clinical trial to further investigate the link between glucosamine-chondroitin and osteoarthritis progression.
In the meantime, patients are advised to weigh the potential risks against benefits with their healthcare providers. The study authors stress that lifestyle changes—such as low-impact exercise and weight management—remain the cornerstone of osteoarthritis management.
